ONCObind™ Procedure Hemoperfusion Filter

Opportunities & Challenges in Metastatic Cancer

Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related deaths.”1 It is estimated that more than 600,000 patients in the United States will die from cancer in 20222, of which 90% will be from metastatic causes.3

Metastatic cancer lacks effective therapies as it is often resistant to chemotherapy, radiation, and immunotherapy. A higher concentration of circulating tumor cells (CTCs) in blood is associated with unfavorable outcomes in metastatic cancer.4

Circulating Tumor Cell Removal Program

ONCObind Procedure for Circulating Tumor Cell Removal
The ONCObind Procedure Hemoperfusion Filter is designed for the adsorption of circulating tumor cells (CTCs) from blood.

The FDA has granted Investigational Device Exemption (IDE) for the ONCObind Procedure, allowing study in patients suffering from metastatic pancreatic ductal adenocarcinoma (PDAC).

LetsConnect Button
1. Fares, J., Fares, M.Y., Khachfe, H.H. et al. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther 5, 28 (2020). https://doi.org/10.1038/s41392-020-0134-x
2. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf 
3. Guan Xiangming, Cancer metastases: Challenges and opportunities, APSB; 5(5)402-18
4. https://www.accessdata.fda.gov/cdrh_docs/pdf7/k071729.pdf

MM-00019 Rev F